U.S. markets closed

  • S&P 500

    3,795.54
    -14.30 (-0.38%)
     

  • Dow 30

    30,991.52
    -68.95 (-0.22%)
     

  • Nasdaq

    13,112.64
    -16.31 (-0.12%)
     

  • Russell 2000

    2,155.35
    +43.38 (+2.05%)
     

  • Crude Oil

    53.79
    +0.22 (+0.41%)
     

  • Gold

    1,846.90
    -4.50 (-0.24%)
     

  • Silver

    25.64
    -0.16 (-0.63%)
     

  • EUR/USD

    1.2160
    +0.0004 (+0.04%)
     

  • 10-Yr Bond

    1.1290
    +0.0410 (+3.77%)
     

  • GBP/USD

    1.3690
    -0.0001 (-0.01%)
     

  • USD/JPY

    103.7600
    -0.0560 (-0.05%)
     

  • BTC-USD

    39,344.10
    +183.31 (+0.47%)
     

  • CMC Crypto 200

    737.14
    +32.52 (+4.62%)
     

  • FTSE 100

    6,801.96
    +56.44 (+0.84%)
     

  • Nikkei 225

    28,698.26
    0.00 (0.00%)
     

Looking Into BlackBerry's Return On Capital Employed

Benzinga Insights
·1 min read

During Q3, BlackBerry's (NYSE:BB) reported sales totaled $224.00 million. Despite a 700.0% in earnings, the company posted a loss of $32.00 million. BlackBerry collected $266.00 million in revenue during Q2, but reported earnings showed a $4.00 million loss.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, BlackBerry posted an ROCE of -0.02%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on BB

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows BlackBerry is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

In BlackBerry's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q3 Earnings Recap

BlackBerry reported Q3 earnings per share at $0.02/share, which beat analyst predictions of $-0.01/share.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Latest Stories

  • Biden's Boom: The $30 Trillion ESG Sector Is Set To Explode In 2021

    The ESG mega-trend sent trillions of dollars pouring in last year. But the real boom could be set to take off beginning January 20th

  • Four things that could pop the 'rational bubble' in equities: Mohamed El-Erian

    Four things could pop the "rational bubble" in equities, says Mohamed El-Erian — even if they're not likely to happen right now.

  • I took care of my late mother for 8 years. Am I obliged to tell my sisters she made me co-owner of a substantial bank account?

    This daughter writes: ‘My conscience is getting the better of me, and I would like to be transparent about being the joint owner of this savings account.’

  • Dow Jones Futures: $1.9 Trillion Biden Stimulus Plan Unveiled; K-Shaped Stock Market Rally Yields Five Breakouts

    Futures edged higher on the $1.9 trillion Biden stimulus plan. The stock market rally faded Thursday, but Airbnb led new breakouts.

  • Marijuana Stocks Jump On Democratic Senate; Are Any Good Buys Now?

    Marijuana stocks surged as a Democratic Senate adds to cannabis legalization momentum. Are any pot stocks good buys now amid profitability challenges?

  • Bank of America's 8 Best Stocks to Buy in Q1

    Here are analysts' top stocks to buy in the first quarter.The S&P 500 closed out 2020 at all-time highs on optimism surrounding additional government stimulus measures and a potential global economic rebound in 2021.

  • Virgin Galactic, Space Stocks Soar As Tesla Bull Eyes New ETF

    Virgin Galactic and other space stocks jumped Thursday on hopes for a new space-focused exchange traded fund.

  • Fastest-Growing Stocks: Square Stock Among 7 Stocks Expecting Up To 156% Growth In 2021

    What are the fastest-growing stocks to watch in 2021? Here's a list featuring GRWG stock, Square, Daqo and four other stocks expecting up to 156% growth.

  • 2 “Strong Buy” Stocks Trading at Steep Discounts

    Whether markets move up or down, every investor loves a bargain. There’s a thrill in finding a valuable stock at low, low price – and then watching it appreciate in the mid- to long-term. The key here for investors is finding options in which the risk/reward combination will work toward long-term advantage. So, how are investors supposed to distinguish between the names poised to get back on their feet and those set to remain down in the dumps? That’s what the pros on Wall Street are here for. Using TipRanks’ database, we pinpointed two beaten-down stocks the analysts believe are gearing up for a rebound. Despite the hefty losses incurred over the past 52 weeks, the two tickers have scored enough praise from the Street to earn a “Strong Buy” consensus rating. Theravance Biopharma (TBPH) We will start with Theravance, a biopharmaceutical company that focuses on developing organ-specific medications. It’s current pipeline includes drug candidates for the treatment of inflammatory lung and intestinal conditions, as well as neurogenicorthostatic hypotension. The research programs range from Phase 1 to Phase 3 trials. Theravance already has YUPELRI on the market as a COPD treatment. YUPELRI underlies the lion’s share of Theravance’s revenue, which in Q3 reach $18.3 million. This was up 47% year-over-year, and was driven by a 124% increase in YUPELRI sales. Of more immediate interest to investors is Trelegy Ellipta, GlaxoSmithKline’s new once daily inhaler medication developed as a maintenance treatment for asthma, which was approved by the FDA in September, 2020. This approval will give Theravance a slice of the income on a drug with a broad potential audience, as asthma affects more than 350 million people globally. Theravance owns royalty rights on Trelegy, with income estimated at 5.5% to 8.5% of total sales. Trelegy was initially approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD. Like many biopharmas, Theravance has high overhead and its approved drugs are at the start of their profitable lives. This keeps the net earnings and revenues down, at least for the near-term, and leads to a discount share price – TBPH has slipped 32% over the past 52 weeks. Covering the stock for Leerink, analyst Geoff Porges remains bullish on Theravance, mainly due to the combination of its robust pipeline and its approved treatments for lung diseases. “Theravance’s respiratory medicines are its key near-term valuation drivers… We still forecast ~$2.4B in WW Triple sales at peak (2027E). Beyond TBPH’s commercial/partnered assets, the company is also developing an improved JAK inhibitor (JAKi) partnered with JNJ (OP) for inflammatory bowel disease (IBD), and a norepinephrine and serotonin reuptake inhibitor (NSRI) TD-9855 (ampreloxetine) for neurogenic orthostatic hypotension (nOH). Each of these drugs leverages novel delivery of unique compounds against proven mechanisms-of-action and could offer superior safety and/or treatment effect, from their wider therapeutic windows,” Porges noted. To this end, Porges rates TBPH an Outperform (i.e. Buy) and gives it a $35 price target, implying an impressive one-year upside of 104%. (To watch Porges’ track record, click here) Overall, there are 5 reviews on file, and all are to Buy, making the Strong Buy consensus unanimous. TBPH shares are priced at $16.95, and their $33.60 average price target suggests a 97% upside from that level. (See TBPH stock analysis on TipRanks) NiSource, Inc. (NI) NiSource is a utility holding company, with subsidiaries in the natural gas and electricity sectors. NiSource provides power and gas to over 4 million customers in Indiana, Kentucky, Maryland, Massachusetts, Ohio, Pennsylvania, and Virginia. The majority of NiSource’s customers, about 88%, are in the gas sector; the company’s electric operations serve customers in Indiana only. The company saw revenues in the third quarter come in at $902 million, down from $962 in the prior quarter and $931 in the year-ago quarter. Overall, however, revenues have conformed to the company’s historic pattern: The second and third quarters are relatively low, while the top line increases with cold weather in Q4 and peaks in Q1. This is typical of utility companies in North America. Despite the lower year-over-year revenues, NiSource has felt confident enough to maintain its dividend payment, holding it steady at 21 cents per common share through 2020. This annualizes to 84 cents, and gives a yield of 3.8%. Not only has the company felt confident to pay income to shareholders, it has also felt confident to invest heavily in renewable energy resources. The company has a FY20 capital spending plan exceeding $1.7 billion, and is guiding toward $1.3 billion for FY21. These expenditures will fund ‘green’ energy projects. NI is currently trading at $21.67, a striking distance from its 52-week low. One analyst, however, thinks this lower stock price gives investors an attractive entry point today. Argus analyst Gary Hovis rates NI a Buy along with a $32 price target. This figure implies a 48% upside from current levels. (To watch Hovis' track record, click here) "NI shares appear favorably valued at 18.1-times our 2021 EPS estimate, below the average multiple of 21.6 for comparable electric and gas utilities," Hovis noted. "NiSource could also become a buyout target, as larger utilitiesand private equity firms have purchased smaller utilities because oftheir stable earnings growth and above-average dividend yields." Overall, Wall Street sees a clear path forward for NiSource – a fact clear from the unanimous Strong Buy consensus rating, based on 3 recent Buy-side reviews. The shares are selling for $21.68, and the average price target of $28.75 suggests an upside of ~32% on the one-year timeframe. (See NI stock analysis on TipRanks) To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • I don’t know if my 3-year-old daughter will go to college, so would saving through my retirement account be more flexible than starting a 529 plan?

    After her birth I wanted to establish a 529 plan. Now that we’re heading into 2021 with all this talk about debilitating college loan debt, I’ve started wondering if it still makes sense to start a brand-new 529 plan or just simply keep contributing to my current 403(b) retirement account, then tapping that early for her, if needed.

  • 8 Top Stocks Will Soar Again In 2021, Analysts Say

    Now's when many investors lament the top stocks they didn't own. But you have a second shot at some if analysts are right.

  • Dow Jones Rallies With '$2 Trillion' Biden Stimulus Plan Due; Intel Surges

    The Dow Jones rallied ahead of the expected unveiling of a massive new coronavirus stimulus plan by President-elect Joe Biden.

  • FuelCell Energy, Plug Power Stocks May Be Out Of Juice: Analyst

    Plug Power and FuelCell Energy received bearish marks from an analyst after they surged in recent months.

  • Buy Shopify, ServiceNow, and 5 Other Cloud Stocks, Says Oppenheimer

    Analyst Brian Schwartz says that investors may need to be more selective this year after last year’s rally in cloud-software stocks.

  • GameStop Stock Is up 100% in Two Days. How Much Higher Can It Go?

    On Wednesday, GameStop (GME) stock recorded its largest ever one day share haul, surging by a massive 57% in the session. This was followed by today's 27% jump. There appears to be some disagreement on Wall Street as to the cause behind the monster moves. As the stock has recently had extremely high short interest, some have put it down to a short squeeze. While Ihor Dusaniwsky, of predictive analytics company S3 Partners, believes the short covering was partly behind the buying spree, he doesn’t see it as the main reason for the surge. Rather, the reason lies elsewhere. “GME’s board shake-up and stronger holiday sales is causing a long-buying tsunami, which is the primary factor for the price move,” Dusaniwsky noted. On Monday, GameStop announced holiday quarter sales increased by 4.8% on a comparable-store basis while the company’s e-commerce sales jumped 308%, although overall sales dropped by 3.1%. Also, on Monday, the video game retailer announced that is refreshing its broad. The company said it hand RC Ventures - one of its largest shareholders - three new seats on the board of directors. One of these will go to Chewy co-founder Ryan Cohen. RC Ventures has previously said GameStop should review its strategy and pivot toward becoming more of a digital-centric technology company. While investors flocked to the stock since the dual announcements, for Wedbush analyst Michael Pachter, the comps figure was “below expectations.” While Pachter believes GameStop is “well-positioned to be a primary beneficiary of the new console launches,” the outlook remains too cloudy for him to truly get behind the stock at present. “The global pandemic remains a hurdle, and we expect it to remain a hurdle until the majority of GameStop’s addressable market is vaccinated. That said, we think that is likely to happen sometime around mid-2021, and we expect GameStop to complete its reboot initiative and the expansion of its ecommerce omnichannel solution by that time,” the analyst said. “We have a positive bias, and we think the company is positioned to generate solid profits in 2021 and beyond, but until we have greater visibility, we are unprepared to upgrade.” Accordingly, Pachter reiterated a Neutral (i.e. Hold) rating on GME shares backed by a $16 price target. Following the recent surge, the figure now suggests downside of ~60%. (To watch Pachter’s track record, click here) There’s even more downside according to the analyst consensus. The average price target stands at $10.72, indicating ~73% drop from current levels. Based on 1 Buy, 3 Holds and 2 Sells, the stock qualifies with a Hold consensus rating. (See GME stock analysis on TipRanks) To find good ideas for growth stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Exxon’s on a 9-Day Winning Streak. Here’s Why.

    As of Thursday afternoon, shares of Exxon (ticker: XOM)—up more than 4% on the day -- were on track for their ninth consecutive gain. A pipeline in the Permian Basin in which the company has a 30% stake won approval from the Federal Energy Regulatory Commission this week. Analysts at both J.P. Morgan and Morgan Stanley are now urging investors to buy the stock.

  • Tesla stock is 'very fully priced,' says investing legend Byron Wien

    Tesla shares look fully valued to investing legend Byron Wien of Blackstone. Here's what Wien told Yahoo Finance Live.

  • Poshmark soars 140% on public debut: Here's how the stock is doing

    Shares of Poshmark (POSH) are soaring more than 140% during the first minutes after its IPO.

  • I’m pregnant, just lost my job to COVID and have $15,000 in a 401(k) — can my husband and I ever retire?

    We regret our lack of retirement savings, though we barely had money to save then. To know if you’re truly on track, or not, you’d have to do a more comprehensive analysis, including how much you expect to need in retirement and what sources of income you’ll have in retirement, such as any personal savings, a pension and Social Security.

  • Fuelcell’s Valuation Deserves a Haircut, Says Analyst

    To say Hydrogen pure-play stocks have rewarded investors handsomely over the past year would be somewhat of an understatement. Several names have delivered massive returns, as investors’ enthusiasm for clean energy stocks has been hard to satiate. Trying to give context to some of these companies’ towering valuations, J.P. Morgan analyst Paul Coster says it’s easier to justify the elevated enterprise value-to-sales multiples “when viewed against the massive long-term growth prospects for these first-movers in the space.” By the 2030s, the hydrogen economy’s global TAM (total addressable market) could be worth between $200 and $400 billion. However, growth prospects aside, when is the lofty multiple no longer justified? Shares of Fuelcell Energy (FCEL), for example, are already up by 59% this year, and by an enormous 752% over the past 12 months. The stock now trades at roughly 50 times price/forward sales and, according to Coster, “looks richly valued.” To this end, Coster downgraded FCEL’s rating from Neutral (i.e. Hold) to Underperform (i.e. Sell). The analyst has a $10 price target for the shares, indicating a severe 43% drop from current levels. (To watch Coster’s track record, click here) That’s not to say Coster thinks Fuelcell is a bad company. In fact, the incoming Biden administration will be friendly to the clean energy sector and should help advance the industry. “We believe policy support will be generally favorable for the fuel cell industry in North America during the Biden administration,” Coster noted, “And we also believe the company’s technology is well positioned for an assortment of de-carbonization applications, including hydrogen production, carbon capture, and low-carbon co-generation solutions.” Coster also lists several reasons which could change his mind to become more “constructive on the stock.” These include earlier than anticipated commercialization of the company’s SOFC (solid oxide fuel cell) technology for use in hydrogen applications, new large-scale contracts other than those currently in backlog, and a “new partnership that accelerates time to market and enables access to end markets beyond current scope.” For now, however, while Coster remains “constructive regarding the Alt Energy sector in general,” and he anticipates the stock to “underperform the mean of [his] coverage over the next 6-12 months.” The rest of the Street appears to think along similar lines. Although 3 additional Holds result in a Hold consensus rating, the average price target is a downbeat one; At $8.63, shares are expected to be changing hands for a 51% discount over the next 12 months. (See FCEL stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.